Basilea-Pfizer’s Cresemba Heads For Indian Debut
Executive Summary
Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its existing portfolio in the segment. Pricing of the product will be keenly watched.
You may also be interested in...
Pfizer’s Vizimpro On Course For India But Competitive Arena Awaits
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.
Basilea's Business Strategy Emboldened By $500m Pfizer Deal
Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.